KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $637.5 million.

  • Royalty Pharma's Cash & Current Investments fell 3542.55% to $637.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $637.5 million, marking a year-over-year decrease of 3542.55%. This contributed to the annual value of $637.5 million for FY2025, which is 3542.55% down from last year.
  • As of Q4 2025, Royalty Pharma's Cash & Current Investments stood at $637.5 million, which was down 3542.55% from $955.0 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Cash & Current Investments registered a high of $2.5 billion during Q2 2022, and its lowest value of $495.3 million during Q4 2023.
  • For the 5-year period, Royalty Pharma's Cash & Current Investments averaged around $1.3 billion, with its median value being $1.2 billion (2021).
  • As far as peak fluctuations go, Royalty Pharma's Cash & Current Investments skyrocketed by 97620.61% in 2021, and later crashed by 7106.92% in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's Cash & Current Investments stood at $1.6 billion in 2021, then rose by 6.53% to $1.7 billion in 2022, then plummeted by 71.07% to $495.3 million in 2023, then soared by 99.31% to $987.2 million in 2024, then crashed by 35.43% to $637.5 million in 2025.
  • Its Cash & Current Investments stands at $637.5 million for Q4 2025, versus $955.0 million for Q3 2025 and $645.1 million for Q2 2025.